Obseva

nature meets nurture

Focused on unmet needs in women's reproductive health

May 2022

Disclaimer

Matters discussed in this presentation may constitute forward-looking statements.

The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from our expectations include our or our licensees' plans for clinical development and commercialization of our product candidates; our planned clinical trials and preclinical studies for our product candidates, including uncertainties inherent in the conduct of clinical trials and clinical development; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and market acceptance of our product candidates; our plans and development of any new indications for our product candidates; our reliance on third parties over which we may not always have full control, and the capabilities of such third parties; our commercialization, marketing and manufacturing capabilities and strategy, including our relationships with third parties related to such activities; our intellectual property position; the impact of the ongoing novel coronavirus outbreak; and our ability to identify and in-license additional product candidates. For further information regarding these risks, uncertainties and other factors that could cause our actual results to differ from our expectations, you should read the risk factors set forth in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on March 10, 2022, and our other filings we make with the Securities and Exchange Commission from time to time.

We expressly disclaim any obligation to update or revise the information herein, including the forward-looking statements, except as required by law. Please also note that this presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the US Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

About ObsEva

ObsEva (NASDAQ: OBSV and SIX: OBSN) is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health.
Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating uterine fibroids, endometriosis and preterm labor.

- Founded in 2012
- Headquarters: Geneva, Switzerland
- Listings: NASDAQ (OBSV) and SIX (OBSN)
- Collaborations with Theramex, Syneos Health, Organon, Kissei, Yuyuan BioScience, Merck Serono

Seasoned leadership team

Brian O'Callaghan
Chief Executive Officer

Petra Pharma
Novartis
Pfizer
Sangart
Merck Serono
Covance

Brandi Howard, PhD
Chief Clinical Officer

Evofem Biosciences
teva

Will Brown
Chief Financial Officer

altimmune
Redmont Advisory Group
pwc
Rheem

Fabien de Ladonchamps
Chief Administrative Officer

addex Therapeutics

Jean-Pierre Gotteland, PhD
Chief Scientific Officer

Pierre Fabre
serono biotech & beyond
preglem reproductive medicine

Clive Bertram
Chief Commercial Officer

Petra Pharma
Sangart
Chiron
Lilly
Pharmion

Luigi Marro
Chief Transformation Officer

FINOX BIOTECH
VCLS Voisin Consulting Life Sciences
Merck Serono

Katja Buhrer
Chief Strategy Officer

KindredBio
MBS Value Partners
citigroup

Board of Directors

Annette Clancy, BSc (Hons)
Chairperson

- GlaxoSmithKline
- sobi
- LYSOGENE

Ernest Loumaye, MD, PhD

- serono biotech & beyond
- IPSEN Innovation for patient care
- preglem reproductive medicine

Brian O'Callaghan

- Petra Pharma
- NOVARTIS
- Pfizer
- Sangart
- Merck Serono
- COVANCE

Anne VanLent

- agtc
- trevi THERAPEUTICS
- Barrier Therapeutics
- SARNOFF Corporation

Ed Mathers

- MedImmune
- GlaxoWellcome

Catarina Edfjäll PhD

- CSL Behring Biotherapies for Life®
- Shire Human Genetic Therapies
- Celgene
- ACTELION A JANSSEN PHARMACEUTICAL COMPANY OF Johnson & Johnson
- Roche

Stephanie Brown

- IPSEN Innovation for patient care
- NOVARTIS
- Takeda
- Biogen
- Genentech A Member of the Roche Group
- MERCK

Investor highlights

1. Pursuing large indications for conditions that compromise **women's reproductive health and beyond**
2. Linzagolix has potential **best in class efficacy, favorable tolerability, and unique flexible dosing options**. NDA accepted; CHMP adopted positive opinion. Licensing agreement with Theramex and commercialization relationship with Syneos Health to support market introduction
3. Global licensing agreement with **Organon to develop and commercialize ebopiprant**, the only known product in development for preterm labor
4. Business model built on strong **global partnerships and collaborations**
5. Seasoned **leadership team** with a track record for success

Product overview

LINZAGOLIX

Potential to relieve symptoms of heavy menstrual bleeding due to uterine fibroids and pain associated with endometriosis[1]

EBOPIPRANT

Potential to delay preterm birth to improve newborn health and reduce medical costs[2]

NOLASIBAN

Potential to improve live birth rate following IVF & embryo transfer

[1]NDA accepted and FDA set a target action date of September 13, 2022 under the Prescription Drug User Fee Act (PDUFA); CHMP adopted a positive opinion in December 2021. Licensing agreement with Theramex and commercialization relationship with Syneos Health

[2] The global development, manufacturing and commercial rights of ebopiprant is licensed to Organon

Multiple development programs drive value

	Phase 1	Phase 2	Phase 3	Key Milestones
LINZAGOLIX Oral GnRH receptor antagonist	Uterine Fibroids – Ph3 PRIMROSE 2 (EU & US)			MAA: CHMP Positive Opinion (Dec 16, 2021) NDA: PDUFA (Sep 13, 2022) Licensing agreement with Theramex and commercialization relationship established with Syneos Health
	Uterine Fibroids – Ph3 PRIMROSE 1 (US)			
			Endometriosis – Ph3 EDELWEISS 3 (EU & US)	Phase 3 positive topline results announced (Q1:22) Phase 3 Post-Rx F/U data expected (Q2:22) Phase 3 Post-Rx F/U-extension data expected (Q4:22)
EBOPIPRANT Oral $PGF_{2\alpha}$ receptor antagonist	Preterm Labor – Ph2b (EU & Asia)			Global rights licensed to Organon
NOLASIBAN Oral oxytocin receptor antagonist	IVF – Ph1/2 (China)			China rights licensed to Yuyuan BioScience

Obseva
nature meets nurture

yselty®
linzagolix

DESIGNED TO TREAT MORE WOMEN SUFFERING FROM UTERINE FIBROIDS

Yselty®, our proposed trade name for linzagolix, is conditionally acceptable for the FDA. Linzagolix has not been approved by FDA for any indication for use. Linzagolix is an investigational drug.

Uterine fibroids

A significant unmet need translating into a multibillion market

$34B/yr
total **US** costs from direct costs, lost workdays and complications

18M
women in the US may be affected by fibroids*

70%+
of women have fibroids by age 50

Quality of Life

premenopausal women may experience heavy menstrual bleeding, anemia, bloating, infertility, pain and swelling

600,000
hysterectomies are performed annually in the US

300,000
are because of uterine fibroids

At least 5M women in the US experience symptoms**

2M women annually seek treatment for heavy menstrual bleeding in the US***

Obseva

Cardozo et al., Am J Obstet Gynecol 2012; Stewart et al. NEJM, 2015; Flynn et al., Am J Obstet Gynecol 2006; Truven Health, Fibroid Foundation website; Epidemiology of women's health, Jones & Bartlett Learning, Ruby T. Senie, 2014
*Uterine fibroids detectable via ultrasound in 70% of Caucasians, 80% of African Americans by age 50 Source: Baird et al, 2003
**Symptomatic in 25-50% of cases Sources: Donnez et al, 2016; Marsh et al, 2018
***Data on file

GnRH antagonist mechanism of action

1. Linzagolix binds competitively to pituitary gland GnRH receptors



4. Gonadotropin suppression leads to dose-dependent decrease in serum estradiol concentration

A potential new gold standard treatment for uterine fibroids

Differentiated PK/PD profile

1

Bioavailability > 80%

2

Half-life 14-15 hours

3

No CYP3A4 induction/food effect

Reliable absorption

Predictable exposure/effect with each dose

Optimal balance for dosing and effectiveness

- Convenient once-daily dosing that fits into women's busy lives
- Blood levels that last long enough to allow flexibility in dosing time

"No hassle" administration profile

- Can be taken with or without food
- No relevant interactions with hormonal add-back therapy, oral iron, calcium or other common medications

Promise of GnRH antagonists

Dose dependent reduction of estradiol (E2)

Women with symptoms of uterine fibroids

No estradiol suppression	Target estradiol	Full estradiol suppression
		
Disease Symptoms – Heavy menstrual bleeding/anemia – Abdominal/pelvic pain and pressure	**Outcomes** – Reduction in bleeding – Minimal to no impact on BMD	**Symptoms/Safety Concerns** – BMD loss – Hot flushes
	***ABT not required**	***ABT required for long term use (>6 months)**

*ABT: 1mg estradiol/0.5 mg norethisterone acetate

Up to 50% of US women suffering from uterine fibroids may have a contraindication to hormonal ABT*

Black women are overrepresented



*US FDA elagolix PI, section 4. Contraindications and section 5.1. Warnings and precautions – thromboembolic disorders and vascular events ** Proportion of individuals with hypertension - Overall population Male vs Female: 47% vs 43% **Hales et al., Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360

Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation ; https://www.cdc.gov/ 2018

Uterine fibroids are ruining lives…

No two women are the same, but millions share a common problem: suffering the daily consequences of uterine fibroids



For long-term use for women for whom ABT is appropriate

Linzagolix 200 mg once daily with concomitant ABT

For long-term use for women with a contraindication to or who prefer to avoid ABT

Linzagolix 100 mg once daily without ABT

For short-term use (up to 6 months) when rapid reduction in fibroid and uterine volume is desired

Linzagolix 200 mg once daily without ABT

ABT-containing regimens may be contraindicated in up to 50% of US women with uterine fibroids based on the elagolix US label* and analysis of CDC data**

*US FDA elagolix PI, section 4. Contraindications and section 5.1. Warnings and precautions – thromboembolic disorders and vascular events

** Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation ; https://www.cdc.gov/2018

The hypothetical patients represented on this slide are for illustrative purposes only as no strength of linzagolix has been approved nor is there FDA-approved Prescribing Information to guide clinical decisions

Phase 3 registration studies

PRIMROSE 1 (US) and PRIMROSE 2 (EU/US)



Primary efficacy endpoint: proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

Patients in the studies received no Vitamin D or calcium supplementation

ABT = Add Back Therapy (1mg estradiol + 0.5 mg norethindrone acetate)

PRIMROSE 1 and 2 achieved primary endpoint for both doses

Responder* analysis at week 24



*Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline
Error bars are 95% CI

PRIMROSE 1 and 2 achieved sustained reduction in MBL

Responder* analysis at week 52



*Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

Significant pain reduction maintained at weeks 52 and 64



Pain assessed on Numerical Rating Scale: 0-10

LGX 200 mg without ABT significantly reduces uterine volume

Substantial reduction compared to placebo & LGX 200 mg with ABT at Week 24



24-week efficacy data support linzagolix as potential best-in-class GnRH antagonist

Caution advised when comparing across clinical trials. Below data are not head-to-head comparison, and no head-to-head trials have been completed, nor are underway



Obseva

Data collected from 6 separate studies

24-week efficacy data support linzagolix as potential best-in-class GnRH antagonist

Caution advised when comparing across clinical trials. Below data are not head-to-head comparison, and no head-to-head trials have been completed, nor are underway

	Linzagolix			Elagolix			Relugolix		
	PRIMROSE 1	PRIMROSE 2	Pooled Analysis	ELARIS 1	ELARIS 2	Pooled Analysis	LIBERTY 1	LIBERTY 2	Pooled Analysis
Dose Regimen	200mg + ABT Once daily			300 mg + ABT Twice daily			40mg + ABT Once daily		
Mean Age (y)	41.6	43.1		42.6	42.5		41.3	42.1	
Baseline MBL (mL per cycle)	197	212		238	229		229	247	
Responder* Rate (RR) (%)	75.5	93.9	84.7	68.5	76.5	72.2+	73.4	71.2	72.3++
Amenorrhea	✓	✓		✓	✓		✓	✓	
Pain	✓	✓		NR	NR		✓	✓	
Fibroid Volume	✗	✓		NR**	NR**		✗	✗	
Uterine Volume	✗	✓		NR**	NR**		✓	✓	
Menstrual Blood Loss	✓	✓		✓	✓		✓	✓	
Anemia	✓	✓		✓	✓		✓	✓	
Quality of Life	✓	✓		✓	✓		✓	✓	

Source: Company information Note: NR = Not reported.
*Primary endpoint: Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline ** P-value not reported
+ Simon et al, Obstet Gynecol 135, 1313-1326 2020 ++ Venturella R et al, ESHRE 2020 abstract.

Minimal BMD change with both doses, plateauing after week 24

Expected age-related BMD decline observed in placebo arm at Week 52



BMD Z-scores remained within normal range

Expected age-related BMD decline observed in placebo arm at Week 52



Z-score compares BMD to the average values of a person of the same age and gender.
A score < -2 is a sign of less bone mass than expected

Favorable tolerability profile

Summary of adverse events—Day 1 to Week 24*

Number (%) of women	PRIMROSE 1			PRIMROSE 2		
	Placebo	Yselty® 100 mg	Yselty® 200 mg + ABT	Placebo	Yselty® 100 mg	Yselty® 200 mg + ABT
	n=104	n=100	n=107	n=105	n=99	n=101
Subject with at least one TEAE	56 (53.8)	65 (65.0)	63 (58.9)	47 (44.8)	50 (50.5)	52 (51.5)
TEAE leading to discontinuation	10 (9.6)	7 (7.0)	10 (9.3)	7 (6.7)	7 (7.1)	7 (6.9)
SAE related to linzagolix	0	0	0	0	1 (1.0)	0
Occurrence of most frequently reported AEs (> 5%) up to week 24						
Hot flush	7 (6.7)	6 (6.0)	7 (6.5)	4 (3.8)	14 (14.1)	13 (12.9)
Headache	6 (5.8)	8 (8.0)	9 (8.4)	6 (5.7)	4 (4.0)	7 (6.9)
Anemia	3 (2.9)	1 (1.0)	4 (3.7)	11 (10.5)	19 (19.2)	9 (8.9)

*No new safety signal identified after Week 24

Rates of adverse events (overall and by preferred term) decreased from Weeks 24-52

Adverse events were rare during the off-treatment follow-up period between Weeks 52 and 76

Obseva

Favorable tolerability profile

Summary of adverse events—week 24 to 52

	PRIMROSE 1			PRIMROSE 2	
	Placebo	Linzagolix 100 mg	Linzagolix 200 mg + ABT	Linzagolix 100 mg	Linzagolix 200 mg + ABT
Number (%) of women	**n=31**	**n=62**	**n=70**	**n=79**	**n=84**
Subject with at least one TEAE	**12 (38.7)**	**25 (40.3)**	**25 (35.7)**	**22 (27.8)**	**21 (25.0)**
TEAE leading to discontinuation	**1 (3.2)**	**2 (3.2)**	**1 (1.4)**	**7 (8.9)**	**1 (1.2)**
SAE related to linzagolix	**0**	**0**	**0**	**0**	**0**
Occurrence after week 24 of most frequently reported AEs (> 5%) up to week 24					
Hot flush	**0**	**1 (1.6)**	**0**	**2 (2.5)**	**3 (3.6)**
Headache	**1 (3.2)**	**3 (4.8)**	**0**	**1 (1.3)**	**1 (1.2)**
Anemia	**1 (3.2)**	**0**	**0**	**2 (2.5)**	**1 (1.2)**

Linzagolix: Potentially “best-in-class” GnRH antagonist

	Linzagolix	Elagolix	Relugolix
Flexible dosing to allow dose dependent reduction of estradiol (E2)	√	X	X
For long-term use for women for whom ABT is appropriate*	84%	72.2%+	72.3%++
For long-term use for women with a contraindication to or who prefer to avoid ABT	56%	X	X
Significant reduction in pain	√	X (NR)	√
Once a day dosing	√	X	√
Favorable bioavailability	>80%	30-50%	11%
Favorable DDI and no food effect**	√	X	X
Favorable tolerability profile	√	√	√
Minimal BMD change	√	√	√

Source: Company information Note: NR = Not reported.
*Primary endpoint: Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline + *Simon et al, Obstet Gynecol 135, 1313-1326 2020* ++ *Venturella R et al, ESHRE 2020 abstract*.
Note: The data on this page are not from head-to-head comparisons.
** In a dedicated food effect study using a single 200 mg dose, there was a decrease of 24% and 36% in AUC and Cmax, respectively, under high-fat meal conditions; however, labelling states elagolix can be taken without regard to meals.
ABT = Add Back Therapy

Obseva

Commercialization relationship with Syneos & licensing agreement with Theramex to realize linzagolix potential

Syneos Health relationship to support commercialization in the United States

- Contract full-service sales and marketing organization
- Extensive launch and women's health experience
- Sales force solely dedicated to Obseva to realize commercial potential
- Maintains control, value and optionality for linzagolix in the US

Theramex agreement to support commercialization outside of the US, Canada and Asia

Royalty rate	
€5 million	Upfront payment to ObsEva
€13.8 million	Development and commercial milestones
€54 million	Sales-based milestones
	Mid-thirties royalties[1]

1 includes the cost of goods sold to Theramex

Linzagolix, designed to treat more women…

Robust clinical data driving differentiated profile



Linxagolix 200 mg once daily with concomitant ABT

For long-term use for women for whom ABT is appropriate

Linxagolix 100 mg once daily without ABT

For long-term use for women with a contraindication to or who prefer to avoid ABT



Linxagolix 200 mg once daily without ABT

For short-term use (up to 6 months) when rapid reduction in fibroid and uterine volume is desired

Potentially best-in-class, only GnRH antagonist to address the non-ABT market ✓

Favorable efficacy rates and tolerability profile compared to other GnRH antagonists for the ABT regimen ✓

Unique set of treatment options and complementary solution for uterine fibroids surgeons for pre-op ✓

Obseva

The hypothetical patients represented on this slide are for illustrative purposes only as no strength of linzagolix has been approved nor is there FDA-approved Prescribing Information to guide clinical decisions

Endometriosis

An emotionally and physically painful condition

$22B/yr
total US costs

176 million
women worldwide suffer from endometriosis

60%+
of women feel symptoms by age 16

Quality of Life

premenopausal women may experience pelvic pain, pain during intercourse and defecation, infertility and emotional distress

Endometriosis affects up to

10%+ in the general population

50%+ in the infertile population

60%+ in patients with chronic pelvic pain

5 million
women in the US are treated annually for endometriosis

Obseva

Cardozo et al., Am J Obstet Gynecol 2012; 2017; Stewart et al. NEJM, 2015; Flynn et al., Am J Obstet Gynecol 2006; Truven Health, Fibroid Foundation website

Phase 2b EDELWEISS in endometriosis



Enrollment 328 patients, ~65/arm

50 sites in US (n=177)

14 sites in EU (n= 151)

Patients were provided with Vitamin D and calcium

* Titration after 12 weeks based on E2 serum level at weeks 4 and 8

**BMD = bone mineral density

Obseva

Phase 2b EDELWEISS in endometriosis



Potential point of differentiation as 75mg partial suppression dose is nearly as effective as 200mg full suppression dose





*p value <0.05 **p value <0.01 ***p value <0.001 for linzagolix doses compared to placebo

Phase 2b EDELWEISS in endometriosis

Sustained improvement in overall endometriosis symptoms (PGIC)



Phase 2b EDELWEISS in endometriosis

75 mg effective without significantly affecting BMD

Mean % change in BMD from baseline to 24 weeks (12 weeks for placebo)



Phase 3 EDELWEISS study design

Overview: multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain

Doses selected based on Phase 2b Edelweiss trial results



Patients who chose not to enter 24-week treatment extension entered post-treatment follow-up

Co-primary endpoints: responder rates for DYS and NMPP



Placebo

LGX 75 mg

LGX 200 mg + ABT

Error bars are 95% CI

Responders defined as women with a reduction in pain and stable or decreased analgesic use

p<0.05 denotes a significant difference from placebo

CI=confidence interval

Obseva
nature meets nurture

Summary of ranked secondary endpoints

Endpoint	Placebo	LGX 75 mg	p-value	LGX 200 mg + ABT	p-value*
Change in DYS score at M6	-0.66	-1.10	<0.001	-1.83	<0.001
Change in NMPP score at M6	-0.66	-0.84	0.048	-0.92	0.002
Change in dyschezia score at M6	-1.41	-1.98	0.015	-1.99	0.012
Change in OPP at M6	-2.19	-2.84	0.024	-3.39	<0.001
Change in difficulty in doing daily activities due to PP at M6	-19.47	-27.37	0.001	-35.60	<0.001
Change in dyspareunia score at M6	-0.82	-1.04	0.100	-1.01	0.184
No analgesic use at M6	13.2%	30.9%	<0.001	44.5%	<0.001
No opiate analgesic use at M6	97.0%	93.8%	0.420	97.0%	1.000

*p<0.05 denotes a significant difference from placebo for each endpoint when p<0.05 for all higher ranked endpoints (including both co-primary endpoints)

Obseva
nature meets nurture

Rapid effects of linzagolix on DYS and NMPP



Obseva
nature meets nurture

Quality of life and intention for surgery

Change from baseline at 6 Months	Placebo	LGX 75 mg	p-value	LGX 200 mg + ABT	p-value
EHP-30 – pain	-19.47	-27.37	0.001	-35.60	<0.001
EHP-30 – control and powerlessness	-21.75	-28.12	0.044	-37.38	<0.001
EHP-30 – emotional well-being	-12.57	-19.04	0.022	-22.03	<0.001
EHP-30 – social support	-13.82	-18.48	0.183	-25.89	<0.001
EHP-30 – self-image	-9.57	-16.43	0.020	-20.69	<0.001
Physician intention for surgery	-0.8	-1.5	0.037	-1.5	0.017
Patient intention for surgery	-0.7	-1.5	0.022	-1.6	0.005

*p<0.05 denotes a significant difference from placebo for each endpoint when p<0.05 for all higher ranked endpoints (including both co-primary endpoints)

Obseva
nature meets nurture

Summary of treatment emergent adverse events (TEAEs)

	Placebo (N=162)	LGX 75 mg (N=160)	LGX 200 mg + ABT (N=162)
Subjects with:	n (%)	n (%)	n (%)
Any TEAE	76 (46.9)	75 (46.9)	92 (56.8)
Severe TEAE	2 (1.2)	5 (3.1)	3 (1.9)
Serious TEAE	0 (0.0)	1 (0.6)	2 (1.2)
Serious TEAE related to LGX	0 (0.0)	0 (0.0)	0 (0.0)
TEAE leading to discontinuation of IMP	3 (1.9)	9 (5.6)	5 (3.1)

Few adverse events > 5% in either linzagolix group

	Placebo (N=162)	LGX 75 mg (N=160)	LGX 200 mg + ABT (N=162)
Subjects with:	n (%)	n (%)	n (%)
Headache	13 (8.0)	13 (8.1)	17 (10.5)
Hot flush	4 (2.5)	12 (7.5)	11 (6.8)
Fatigue	4 (2.5)	6 (3.8)	11 (6.8)

Minimal percent change from baseline in BMD at week 24



Obseva
nature meets nurture

BMD Z-scores remained within normal range



Z-scores compare BMD to the average values of a person of the same age and gender.
A score < -2 is a sign of less bone mass than expected

Obseva
nature meets nurture

Phase 3 EDELWEISS 3 Summary

Co-primary endpoints

Linzagolix **200 mg with ABT met both co-primary objectives** of reduction in DYS and NMPP at 3 months; Linzagolix 75 mg met DYS but did not meet NMPP

Secondary endpoints

Linzagolix **200 mg with ABT provided statistically significant and clinically meaningful improvements at 6 months in ranked secondary endpoints** of DYS and NMPP, dyschezia, overall pelvic pain and daily activities; Linzagolix **75 mg also showed improvements in these endpoints**

Safety and tolerability

Both doses **well-tolerated with minimal BMD decrease** and few TEAEs >5% in either linzagolix arm

Next steps

Results support **further development of ABT and non-ABT doses of linzagolix** in the endometriosis indication

ABT=add-back therapy (Estradiol 1mg/Norethisterone Acetate 0.5mg)
DYS=dysmenorrhea
NMPP=non-menstrual pelvic pain
BMD=bone mineral density
TEAEs=treatment emergent adverse events

Obseva
nature meets nurture

Prostate cancer

The second most prevalent form of cancer in men and a leading cause of death due to cancer[1]

3.8%

Of all cancer deaths in men in 2018 due to prostate cancer[2]

1.3M

New cases of prostate cancer reported globally in 2018[3]

2X Mortality Rate

In African-American men compared to Caucasians; incidence rate of 158.3 new cases diagnosed per 100K African-American men[4]

~130K

Number of patients in the US treated with Lupron

$600M

Total US sales for GnRH agonists

Lupron was the biggest product in the US with nearly $350M in revenue

$2.1B

Total global prostate cancer market for GnRH agonists in 2020[5]

Or over half of the total global GnRH agonist market[6]

Obseva

[1-4.] World J Oncol. 2019. 10; 63
[5]. IMS MIDAS data, monthly audit Dec 2020
[6]. Evaluate Pharma, aggregation of brokers forecast, 2020

Advanced prostate cancer opportunity

Current Standard of Care	Aims to reduce testosterone (T) to castration levels
Limitations	Injectable GnRH agonists (leuprolide) most commonly used but associated with initial T level spike that can worsen symptoms and delay recovery upon drug discontinuation
Benefit of GnRH Antagonists	Evidence from pooled analyses suggest lower cardiovascular risk with GnRH antagonists versus GnRH agonists[1]
Paradigm Change	Once-daily oral drugs that can safely and effectively suppress T levels would represent a paradigm change in chronic treatment of the disease
Superiority of relugolix	Myovant's relugolix (Orgovyx™) demonstrated superiority in Phase 3 versus Lupron and launched in January 2021

Obseva

[1] Albertsen et al., Eur Urol. 2014. 65; 565

GnRH analogues in prostate cancer*

Profile			Efficacy††				Safety		
GnRH analog	Delivery Route	Flare Effect†	Castration on Day 4 (%)	Castration on Day 15 (%)	Sustained T Level to 48 Weeks (%)	PSA Response at Day 15 (%)	MACE‡ Overall/Prior History (%)	Injection Site Reaction (%)	Hot Flush (%)
GnRH Agonist									
Leuprolide	Injection (Every 1-3 months)	Yes	0	12	89	20	6.2/17.8	14	51.6
Degarelix§	Injection (Monthly)	No	96	99	97	-	-	40	26.0
Relugolix	Oral	No	56	99	97	79	2.9/3.6	n/a	54.3

*Phase 3 relugolix (HERO) results for leuprolide and Relugolix (Shore et al., NEJM. 2020; 382: 2187 -96 ; Degarelix package insert (PI)
†Flare effect = initial spike in T levels upon treatment initiation due to initial activation of GnRH receptor
††Responder = Testosterone levels <50 ng/dL (i.e., castration)
‡MACE=major cardiovascular event after 48 weeks of treatment; KM analysis showed 54% lower risk in relugolix group vs leuprolide group
§Degarelix PI: Day 3 and Day 14; sustained levels to Day 364 for 240/80mg dose; *rate of hot flush for leuprolide in Degarelix studies was 21%

Obseva

ObsEva's linzagolix could potentially challenge the current standard of care as the best-in-class oral GnRH antagonist

Potentially best-in-class GnRH antagonist in uterine fibroids & endometriosis

ObsEva exploring development of linzagolix in combination with estrogen for the treatment of advanced prostate cancer

Potential improvement on GnRH antagonist-only regimen by further decreasing cardiovascular & bone loss risk, and mitigating hot flushes: Phase 3 results showed similar hot flush rates (>50%) for relugolix and leuprolide[1]

Commercialization relationship with Syneos Health offers the best option to maximize and maintain control, value and optionality in the U.S. Licensing agreement with Theramex, a leading global pharmaceutical company specializing in women's health, supports the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia

[1] Shore et al., NEJM. 2020; 382:2187-96

Obseva
nature meets nurture

EBOPIPRANT

POTENTIAL TO DELAY PRETERM BIRTH TO IMPROVE NEW BORN HEALTH AND REDUCE MEDICAL COSTS

GLOBAL LICENSING AGREEMENT WITH ORGANON

Preterm birth is delivery before 37 weeks of pregnancy

Life altering & costly

$26B/yr
US economic burden

>1
In 10 babies are born preterm

1 million
preterm related deaths in 2015 WW[1]

LEADING
cause of death in children under age 5

Babies surviving early birth face greater likelihood of lifelong disabilities

Preterm birth, a costly burden per baby

$16.9B+ US infant medical costs

$195K+ average cost per US survivor infant born 24-26 weeks

$50K average US cost for a preterm infant

Obseva

WHO 'Born Too Soon: The Global Action Report on Preterm Birth' (2012); Kissin et al. NEJM, 2014
Behrman et al., National Academies Press, 2007
[1]WHO: 15 million babies born preterm each year worldwide, and number is rising.

Ebopiprant: an advancement in treatment of preterm labor

Orally active, selective prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) receptor antagonist



ebopiprant
Selectively blocks the $PGF2_{2\alpha}$ receptor

Ebopiprant, a potential breakthrough for preterm labor

with improved safety over non-selective COX *inhibitors (NSAIDS)

No FDA–approved preterm labor treatment available in US
Use in setting of active preterm labor and threatened premature delivery

*COX: cyclooxygenase

Global license, development and commercialization agreement with Organon optimizes Ebopiprant value



ObsEva entitled to receive tiered double-digit royalties on commercial sales

$25 million	Upfront payment to ObsEva
$90 million	Development and regulatory milestones
$385 million	Achievements in commercial milestones

ObsEva Financial Summary

Facilities and agreements in place to fund operations

$58 million
total cash on hand at March 31, 2022

$135 million
borrowing capacity under convertible note agreement[1]

$25 million
total ATM capacity at March 31, 2022

Strategic agreements

ObsEva actively engages with partners to advance its pipeline and build shareholder value. Total deal value of out-licensing agreements include:

$500M *plus tiered double-digit royalties for ebopiprant worldwide rights with Organon*

€72.8M *plus mid-thirties royalties[2] for linzagolix ex US/Canada/Asia rights with Theramex*

$132M *plus up-to tiered double-digit royalties for nolasiban China rights with Yuyuan*

ObsEva

1 subject to certain funding conditions
2 includes the cost of goods sold to Theramex

Investor highlights

1. Pursuing large indications for conditions that compromise **women's reproductive health and beyond**
2. Linzagolix has potential **best in class efficacy, favorable tolerability, and unique flexible dosing options**. NDA accepted; CHMP adopted positive opinion. Licensing agreement with Theramex and commercialization relationship with Syneos Health to support market introduction
3. Global licensing agreement with **Organon to develop and commercialize ebopiprant**, the only known product in development for preterm labor
4. Business model built on strong **global partnerships and collaborations**
5. Seasoned **leadership team** with a track record for success

Thank you

Obseva